NEW YORK (GenomeWeb News) – Saladax Biomedical has appointed Mark Myslinski to the posts of senior VP and chief commercial officer. Myslinski recently was president and CEO of RedPath Integrated Pathology, where he helped to move the company from research and development to commercialization of a molecular diagnostic assay in a CLIA lab. He also has served as VP of evidence-based medicine at Ortho Clinical Diagnostics and as GM of molecular and cellular diagnostics at Veridex.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.